Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2005-04-12
2005-04-12
Swartz, Rodney P (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S009200, C424S093100, C424S184100, C424S234100, C424S278100, C435S041000, C435S243000, C435S253100, C435S863000
Reexamination Certificate
active
06878377
ABSTRACT:
Antigenic and/or immunogenic material derived fromMycobacterium vaccaeis used to down-regulate Th2 activity of the immune system without up-regulation of Th1 activity. Disorders such as Chronic Fatigue Syndrome, Gulf War Syndrome and Total Allergy Syndrome are treated. The material preferably comprises deadM. vaccaecells in a composition which does not include a non-M. vaccaeantigen, immunogen or allergen.
REFERENCES:
patent: 4724144 (1988-02-01), Rook et al.
patent: WO 85 05034 (1985-11-01), None
patent: WO 91 02542 (1991-03-01), None
patent: WO 92 08488 (1992-05-01), None
patent: WO 93 16727 (1993-09-01), None
patent: WO 94 06466 (1994-03-01), None
patent: WO 95 26742 (1995-10-01), None
patent: WO 96 11014 (1996-04-01), None
Evans, “Chronic Fatigue Syndrome: thoughts on pathogenesis”, Reviews of Infectious Diseases 13(suppl. 1):S56-S59 (1991).
Sharfran et al, “The Chronic Fatigue Syndrome ”, The American Journal of Medicine 90:730-739 (1991).
Herberman, “Sources of Confounding in Immunologic Data”, Reviews of Infectious Diseases 13(suppl. 1):S84-S86 (1991).
Shulte, “Validation of biologic markers for use in research on Chronic Fatigue Syndrome”, Reviews of Infectious Diseases 13(suppl. 1):S87-S89 (1991).
Holmes, “Defining the Chronic Fatigue Syndrome”, Reviews of Infectious Diseases 13(suppl. 1):S53-S55 (1991).
Holmes, “Chronic Fatigue Syndrome: A working case definition”, Annals of Internal Medicine 108:387-389 (1991).
Grange et al, “Role of viral infections in the inception of childhood asthma and allergies”, Thorax 50:701 (1994).
Seah and Rook, “A sensitive, non-radioactive quantitative method for measuring IL-4 and IL4δ2 mRNA in unstimulated cells from multiple clinical samples, using nested RT-PCR”, Journal of Immunological Methods 228:139-149 (1999).
Seah et al, “Type 2 Cytokine Gene Activation and Its Relationship to Extent of Disease in Patients with Tuberculosis”, The Journal of Infectious Diseases 181:385-389 (2000).
Yang et al, “Murine studies using polyethylene glycol-modified recombinant human interleukin 2 (PEAG-IL-2): antitumor effects of PEG-alone and in combination with adoptive cellular transfer”, Lymphokine Cytokine Res. 10(6):475-480 (1991)—Abstract.
Cameron et al, “Synergistic antitumor activity of tumor-infiltrating lymphocytes interleukin 2, and local tumor irradiation. Studies on the mechanism of action”, J. Exp. Med. 171(1):249-263 (1990)—Abstract.
Cameron et al, “Synergistic antitumor effects of combination immunotherapy recombinant interleukin-2 and a recombinant hybrid alpha interferon in the treatment of established murine hepatic metastases”, Cancer Res. 48(20):5810-5817 (1988)—Abstract.
Papa et al, “Combined effects of chemotherapy and interleukin 2 in the therapy of mice with advanced pulmonary tumors”, Cancer Res. 48(1):122-129 (1988)—Abstract.
Lotze et al, “In vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration”, Cancer Res. 47(8):2188-2195 (1987)—Abstract.
Schwartzentruber, “Guidelines for the safe administration of high-dose interleukin-2”, J. Immunother. 24(4):287-293 (2001)—Absract.
Scott et al, “Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine”, Ann. Rheum. Dis. 60(10):913-923 (2001)—Abstract.
Kalden et al, “Improved functional ability in patients with rheumatoid arthrtis-longterm treatment with leflunomide versus sulfasalazine”, J. Rheumatol 28(9):1983-1991 (2001)—Abstract.
Burkhardt and Kalden, “Xenobiotic immunosuppressive agents: therapeutic effects in animal models of autoimmune diseases”, Rheumatol. Int. 17(3):85-90 (1997)—Abstract.
Guo et al, “Immunosuppression preventing concordant xenogeneic islet rejection is not sufficient to prevent recurrence of autoimmune diabetes in nonobese diabetic mice”, Transplantation 65(10):1310-1314 (1998)—Abstract.
Xu et al, “In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ. lpr/lpr mice”, J. Immunol. 159(1):167-174 (1997)—Abstract.
Jarman et al, “Inhibition of murine lgE and immediate cutaneous hypersensitivity responses to ovalbumin by the immunomodulatory agent leflunomide”, Clin. Exp. Immunol. 115(2):221-228 (1999)—Abstract.
Stosic-Grujicic et al, “Leflunomide protects mice from multiple low dose streptozotocin (MLD-SZ)-induced insulitis and diabetes”, Clin. Exp. Immunol. 117(1):44-50 (1999)—Abstract.
Borish et al, “Chronic fatigue syndrome: Identification of distinct subgroups on the basis of allergy and psychologic variables”, J. Allergy Clin. Immunol. 102(2):222-230 (1998).
Straus et al, “Allergy and the chronic fatigue syndrome”, Allergy Clin. Immunol. 81(5), Part 1:791-795 (1988).
Chao et al, “Altered Cytokine Release In Peripheral Blood Mononuclear Cell Cultures From Patients With The Chronic Fatigue Syndrome”, Cytokine 3(4):292-298 (1991).
Bennett et al, “Elevation of Bioactive Transforming Growth Factor-βin Serum from Patients with Chronic Fatigue Syndrome”, Journal of Clinical Immunology 17(2):160-166 (1997).
Visser et al, “CD4 T Lymphocytes from Patients with Chronic Fatigue Syndrome Have Decreased Interferon-γ Production and Increased Sensitivity to Dexamethasone”, The Journal of Infectious Diseases 177:451-454 (1998).
Conti et al, “Eosinophil cationic protein serum levels and allery in chronic fatigue syndrome”, Allergy 51:124-127 (1996).
Wang & Rook, “Inhibition of an established allergic response to ovalbumin in BALB/c mice by killedMycobacterium vaccace”, Immunology 93:307-313 (1998).
Tükenmez et al, “Effect of pre-immunization by killedMycobacterium bovisandvaccaeon immunoglobulin E response in ovalbumin-sensitized newborn mice”, Pediatric Allergy Immunol. 10:107-111 (1999).
Cottrez et al, “T Regulatory Cells 1 Inhibit a Th2-Specific Response In Vivo”, The Journal of Immunology 165:4848-4853 (2000).
Zuany-Amorim et al, “Suppression of airway eosinophilia by killedMycobacterium vaccae-induced allergen-specific regulatory T-cells”, Nature Medicine 8(6):625-629 (2002).
Arkwright et al, “Intradermal administration of a killedMycobacterium vaccaesuspension (SRL 172) is associated with improvement in atopic dermatitis in children with moderate-to-severe disease”, J. Allergy Clin. Immunol 107:531-534 (2001).
Breivik & Rook, “Prevaccination with SRL 172 (heat-killed Mycobacterium vaccae) inhibits experimental periodontal disease in Wistar rats”, Clin. Exp. Immunol. 120:463-467 (2000).
Rook and Zumla, “Gulf Ware syndrome: is it due to a systemic shift in cytokine balance towards a Th2 profile?”, 349:1831-1833 (1997).
Wallace et al, “A type 2 (Th2-like) pattern of immune response predominates in the pulmonary interstitium of patients with cryptogenic fibrosing alveolitis (CFA)”, Clin. Exp. Immunol. 101:436-441 (1995).
Wynn et al, “An IL-12 based vaccination method for preventing fibrosis induced by schistosome infection”, Nature 376:594-597 (1995).
Lawrence et al, “IL-4-regulated enteropathy in an intestinal nematode infection”, Eur. J. Immonol. 28:2672-2684 (1998).
Seah and Rook, “IL-4 Influences Apoptosis of Mycobacterium-Reactive Lymphocytes in the Prsence of TNF-α”, The Journal of Immunology 167:1230-1237 (2001).
Lee et al, “Interleukin-13 Induces Tissue Fibrosis by Selectively Stimulating and Activating Tr
Rook Graham A.
Stanford John L.
Zumla Alimuddin L.
Nixon & Vanderhye PC
Stanford Rook Limited
Swartz Rodney P
LandOfFree
Mycobacterium vaccae for down-regulation of the Th2 activity... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mycobacterium vaccae for down-regulation of the Th2 activity..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mycobacterium vaccae for down-regulation of the Th2 activity... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3442097